Skip to main content

Table 1 Patient, tumor, and treatment characteristics

From: Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors

Parameter Cohort (n = 70)
Patients-no. 70
Tumors (targets)-no. 76
Follow-up time-median (range) 15 (8–22) months
Median age-median (range) 74 (54–91) years
Sex  
 M-no. (%) 28 (40.0)
 F-no. (%) 42 (60.0)
Location  
 Right upper lobe-no. (%) 18 (23.7)
 Right middle lobe-no. (%) 4 (5.3)
 Right lower lobe-no. (%) 14 (18.4)
 Left upper lobe-no. (%) 14 (18.4)
 Left lower lobe-no. (%) 26 (34.2)
 Central 28 (36.8)
 Peripheral 48 (63.2)
Metastatic-no. (%) 2 (2.9)
Lung Primary-no. (%) 68 (97.1)
Histology  
 Adenocarcinoma 40 (57.1)
 Squamous 17 (24.3)
 NSCLC-NOS 11 (15.7)
Tumor Size-median (range) 2.3 (0.6–5.5) cm
 ≤3 cm 53 (69.7)
 >3 cm 23 (30.3)
Median GTV (range) 6.6 (0.3–150.4) cc
Median PTV (range) 20.8 (12.4–308.2) cc
Median total dose (range) 50 (25–60) Gy
 1 fraction (%) 19 (27.1 %)
 3–8 fractions (%) 51 (72.9 %)
  1. Abbreviations: NSCLC non-small-cell lung cancer, NOS Not otherwise specified, GTV gross tumor volume, PTV planning target volume